论文部分内容阅读
LAK疗法是一种过继性免疫疗法(adoptive im-munotherapy)。是将恶性肿瘤患者的淋巴细胞,经淋巴因子白介素-2(IL-2)诱导,再经体外培养诱导为非特异性杀伤细胞。然后,将这种淋巴因子激活的杀伤(LAK)细胞回输给患者的方法。Rosenberg等(1985年末)首次报道用本法治疗用其他疗法无效的晚期癌症25例,肿瘤缩小者11例,消失者1例,从而引起全世界的普遍关注。作者用本法治疗原发性肝癌有效者9例。方法是取静脉血,分离出10~9～10~(10)个淋巴细胞,与重组白介
LAK therapy is an adoptive im-munotherapy. The lymphocytes of patients with malignant tumors were induced by lymphokine interleukin-2 (IL-2) and induced by non-specific killer cells in vitro. Then, the method of returning this lymphokine activated killer (LAK) cell to the patient. Rosenberg et al. (Late 1985) reported for the first time that 25 cases of advanced cancers that were ineffective with other therapies were treated with this method. Tumors were reduced in 11 cases and disappeared in 1 case, causing widespread concern in the world. The authors used this method to treat 9 cases of primary liver cancer. The method is to take venous blood, isolate 10~9~10~10 lymphocytes, and recombine